Study Identifies NSD2 Inhibition as a Method to Reverse Drug Resistance in Neuroendocrine Prostate Cancer

A recent study published in *Nature* has identified a potential method to address drug resistance in neuroendocrine prostate cancer (CRPC-NE), one of the most challenging forms of prostate cancer to treat. Researchers found that targeting the epigenetic regulator NSD2 can reverse resistance to androgen receptor (AR) inhibitors, including enzalutamide, a commonly used treatment for advanced prostate cancer. This discovery highlights a possible therapeutic strategy for restoring drug sensitivity in patients with CRPC-NE.

The study focused on the role of NSD2, an epigenetic factor known to influence gene expression without altering DNA sequences. Researchers observed that NSD2 contributes to the development of drug resistance in CRPC-NE by modifying chromatin structure and disrupting AR signaling pathways. By inhibiting NSD2 activity, they were able to restore responsiveness to AR-targeted therapies such as enzalutamide in preclinical models. The findings suggest that NSD2 plays a critical role in driving treatment resistance and could serve as a promising target for future interventions aimed at improving outcomes for patients with this aggressive form of prostate cancer.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

Related posts:

Contactless System Using Radio Waves and AI Detects Atrial Fibrillation Remotely Mercalis and PharmaCord Merge to Form Valeris Focused on Streamlining Pharmaceutical Commercialization Moderna and Novavax Cite Data from Trials Involving Over 70,000 Participants to Address Vaccine Effectiveness Study Analyzes Impact of Green Spaces and Extreme Heat on Hypertension in Elderly Chinese Population

Author

GOAI